Attenuation of  in vitro drug resistance phenotype following culture adaptation compared to fresh clinical isolates in Cambodia by unknown




falciparum in vitro drug resistance phenotype 
following culture adaptation compared to fresh 
clinical isolates in Cambodia
Suwanna Chaorattanakawee1, Charlotte A. Lanteri1,5, Siratchana Sundrakes1, Kritsanai Yingyuen1, 
Panita Gosi1, Nitima Chanarat1, Saowaluk Wongarunkochakorn1, Nillawan Buathong1, Soklyda Chann1, 
Worachet Kuntawunginn1, Montri Arsanok1, Jessica T. Lin2, Jonathan J. Juliano2, Stuart D. Tyner1,4, 
Mengchuor Char3, Chanthap Lon1* and David L. Saunders1
Abstract 
Background: There is currently no standardized approach for assessing in vitro anti-malarial drug susceptibility. 
Potential alterations in drug susceptibility results between fresh immediate ex vivo (IEV) and cryopreserved culture-
adapted (CCA) Plasmodium falciparum isolates, as well as changes in parasite genotype during culture adaptation 
were investigated.
Methods: The 50 % inhibitory concentration (IC50) of 12 P. falciparum isolates from Cambodia against a panel of 
commonly used drugs were compared using both IEV and CCA. Results were compared using both histidine-rich 
protein-2 ELISA (HRP-2) and SYBR-Green I fluorescence methods. Molecular genotyping and amplicon deep sequenc-
ing were also used to compare multiplicity of infection and genetic polymophisms in fresh versus culture-adapted 
isolates.
Results: IC50 for culture-adapted specimens were significantly lower compared to the original fresh isolates for both 
HRP-2 and SYBR-Green I assays, with greater than a 50 % decline for the majority of drug-assay combinations. There 
were correlations between IC50s from IEV and CCA for most drugs assays. Infections were nearly all monoclonal, with 
little or no change in merozoite surface protein 1 (MSP1), MSP2, glutamate-rich protein (GLURP) or apical membrane 
antigen 1 (AMA1) polymorphisms, nor differences in P. falciparum multidrug resistance 1 gene (PfMDR1) copy number 
or single nucleotide polymorphisms following culture adaptation.
Conclusions: The overall IC50 reduction combined with the correlation between fresh isolates and culture-adapted 
drug susceptibility assays suggests the utility of both approaches, as long as there is consistency of method, and 
remaining mindful of possible attenuation of resistance phenotype occurring in culture. Further study should be 
done in higher transmission settings where polyclonal infections are prevalent.
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Background
In vitro drug susceptibility testing is widely used as a 
tool for surveillance of drug-resistant Plasmodium fal-
ciparum. There are two commonly used approaches to 
examine parasite in  vitro drug susceptibility: assess-
ing parasites isolated directly from patients (sometimes 
referred to as ‘immediate ex vivo’ or IEV), and from cryo-
preserved isolates that are subsequently culture-adapted. 
Culture adaptation offers convenience in sample collec-
tion and transport to a reference laboratory, particularly 
where there are limited field facilities to perform ex vivo 
assays on fresh isolates. However, the culture adaptation 
process at the reference laboratory is more labour inten-
sive compared to the immediate ex  vivo method. Fur-
ther, recovery from cryopreservation can be a significant 
problem, thereby lowering the yield of the assay. While it 
has been argued that culture-adapted isolates represent 
the intrinsic drug susceptibility of parasites, regardless of 
host immunity and pharmacokinetics, it remains unclear 
whether the isolates retain their susceptibility profiles 
following adaptation, or whether some resistance charac-
teristic may be attenuated in culture [1].
IEV assays on parasites isolated directly from patients 
are favoured by others, who argue that parasites adapted 
in culture are attenuated and therefore may not retain 
the genotype/phenotype of the original clinical isolates. 
This is particularly true for those genes which the para-
site may have had to modify to survive in the presence of 
drug, and which may carry a fitness cost for the parasite. 
Several studies on parasite population dynamics demon-
strated clonal fluctuations and selection of resistant gen-
otypes during malaria treatment [2–4] with evidence of 
loss of parasite population characteristics during culture 
adaptation [5–7].
There is currently no standardized approach for assess-
ing malaria drug susceptibility. In most cases, assays used 
depend on availability of field laboratory facilities and 
laboratory proximity to the collection sites. Ex vivo assays 
on fresh parasite isolates or short-term clinical isolate 
cultures intended to increase parasitaemia are favoured 
where adequate field laboratory facilities are available, 
while cryopreserved samples are preferred where field 
capacity is limited, but there is a well-developed central 
reference laboratory [8–10]. In some settings where ref-
erence laboratory proximity and transport times permit, 
P. falciparum isolates are stored at 4  °C for a few days 
without cryopreservative solution until transported for 
culture adaptation and drug testing [11].
There have been limited reports comparing para-
site drug susceptibility results amongst the various 
approaches. Only one direct head-to-head comparison 
of drug sensitivity results before and after culture adap-
tation of the same isolates showed that chloroquine 
(CQ)-resistant isolates can maintain their resistance 
phenotype during in vitro cultivation, while isolates ini-
tially sensitive to CQ may develop resistance in culture 
[12]. Limited data on other drugs tested were incon-
clusive and corresponding parasite genetic changes 
were not explored. The aims of the current study were 
to investigate potential alterations in drug suscepti-
bility results between fresh IEV and cryopreserved 
culture-adapted isolates, and explore parasite popula-
tion dynamics during culture adaptation. IC50 results 
from IEV and culture-adapted Cambodian isolates were 
compared head-to-head using histidine-rich protein-2 
(HRP-2) ELISA and SYBR Green I fluorescence assays. 
Selected parasite antigenic and drug resistance loci of 
interest were compared between the original and post-
culture isolates. The results illustrate the utility of both 
approaches, but suggest that parasite drug resistance 
phenotypes may be attenuated during the parasite cul-
tivation process, highlighting limitations on results 
comparability between IEV and culture-adapted drug 
susceptibility assessments.
Methods
Plasmodium falciparum isolate collection and specimen 
processing
To compare drug susceptibility results arising from 
fresh isolates with those from culture-adapted parasites 
derived from cryopreserved samples, 20 P. falciparum 
isolates were obtained from volunteers with uncom-
plicated mono P. falciparum infection enrolled in the 
in  vitro resistance surveillance study (WRAIR#1576), 
conducted in multiple provinces of Cambodia (Pailin, 
Oddar Meancheay, Kampong Speu). A different set of 29 
P. falciparum isolates from a clinical DHA-piperaquine 
study (WRAIR#1877) in Oddar Meancheay [13] was used 
to examine the effect of white blood cells (WBC) in cul-
ture on ex  vivo drug susceptibility testing. The studies 
were approved by the Cambodian National Ethics Com-
mittee for Health Research (NECHR), and the Walter 
Reed Army Institute of Research (WRAIR) Institutional 
Review Board. All subjects were ≥13  years old without 
a history of anti-malarial drug use within the previous 
7 days (WRAIR#1576) or 28 days (WRAIR#1877). Diag-
nosis of malaria was conducted using Giemsa-stained 
peripheral blood smears as reported elsewhere [10]. At 
the time of diagnosis (before treatment), patient blood 
samples were collected in heparinized tubes, processed 
for parasite cryopreservation and tested for ex vivo drug 
susceptibility at the field laboratory within 4  h of phle-
botomy. The cryopreserved samples were shipped to 
the main laboratory for establishing in  vitro culture to 
test for in  vitro drug susceptibility. A portion of blood 
samples were collected in EDTA tubes, and shipped to 
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the main laboratory for DNA preparation and parasite 
molecular analysis.
Dried drug plate coating
Dihydroartemisinin (DHA), artesunate (AS), mefloquine 
hydrochloride (MQ), quinine sulfate hydrate (QN), and 
chloroquine diphosphate (CQ) were coated onto 96-well 
plates using published methods [14, 15]. Threefold serial 
drug dilutions were performed on plates to reach final 
concentrations ranging from 0.027 to 20 ng/ml for DHA 
and AS, 0.274 to 200 ng/ml for MQ, 1.71 to 1250 ng/mL 
for QN, and 2.74 to 2000 ng/ml for CQ. The top row of 
each plate served as a drug-free control. Drug plates were 
dried overnight in a running biosafety cabinet and stored 
at 4  °C up to 8  weeks prior to use. As a quality control 
for dried drug plate integrity, a sub-set of plates not used 
in the assays was tested to ensure an acceptable range of 
IC50 values was attained against the P. falciparum W2 
reference clone, as described previously [14, 15].
Plasmodium falciparum culture and drug susceptibility 
testing
For immediate ex  vivo (IEV) drug susceptibility assay, 
whole blood samples from malaria patients were adjusted 
to 1.5 % haematocrit with 0.5 % Albumax RPMI 1640 and 
applied to dried drug plates at the field laboratory, with-
out prior culture adaptation or centrifugation. Samples 
with >0.5 % parasitaemia were first diluted to 0.2–0.5 % 
by adding 50  % haematocrit human O+  red blood cells 
(RBCs) in 10  % serum RPMI 1640 culture media, prior 
adjusted to 1.5 % haematocrit with 0.5 % Albumax RPMI 
1640. Plates were incubated at 37 °C using a candle jar for 
72 h, after which plates were frozen and shipped to the 
main laboratory for parasite growth assessments using 
HRP-2 ELISA and SYBR Green I assays following pub-
lished methods [14, 16].
To compare the drug susceptibility profiles attained 
from fresh and culture-adapted parasites, 20 cryopre-
served P. falciparum isolates with parasitaemia  >0.5  % 
were chosen for recovery, in vitro cultivation and in vitro 
drug susceptibility testing. All isolates were collected 
from patients negative for pre-existing anti-malarial 
activity in plasma, confirming no recent anti-malarials 
use [10]. Cryopreserved samples in a glycerol mixed solu-
tion were recovered as previously described [17]. Con-
tinuous culture was performed using a modified Trager 
and Jenson method [18]. Parasites were synchronized 
utilizing 5 % d-sorbitol as previously described [19], and 
maintained for another 48 h prior to performance of drug 
susceptibility assays. For drug susceptibility testing, syn-
chronized cultures with ≥90 % ring forms were diluted to 
0.5 % parasitaemia with 1.5 % haematocrit in 0.5 % Albu-
max RPMI 1640, and transferred to dried drug-coated 
plates as described previously. Plates were incubated at 
37 °C with 5 % CO2, 5 % O2 and 90 % N2 for 72 h. Parasite 
growth inhibition was assessed using the HRP-2 ELISA, 
and SYBR Green I assay following published methods 
[14, 16]. During 1–2 months of in vitro culture, three to 
seven replicate IC50 assays were run on culture-adapted 
parasites for each isolate, and average IC50 were com-
pared with those obtained from ex vivo testing on fresh 
samples.
In order to assess the effect of WBC on ex  vivo drug 
susceptibility testing, 29 fresh P. falciparum isolates 
with varying parasitaemia (0.07–4.12  %) were used, as 
described above. A portion of the blood specimen was 
centrifuged and after removing the buffy coat, packed 
RBCs were mixed with the media as described above, and 
applied to the drug plate. The results were compared side 
by side with those obtained from whole blood samples.
Parasite molecular analysis
Genomic DNA was extracted from EDTA blood using a 
Qiagen DNA extraction kit (QIAGEN, USA) according to 
the manufacturer’s instructions. Parasite genotyping was 
done using both nested PCR at polymorphic regions of 
the merozoite surface protein 1 (MSP1) block 2, MSP 2 
(block 3), and glutamate-rich protein (GLURP) R2 repeat 
region to evaluate for size variation and allelic-families 
[20, 21] and by amplicon deep sequencing of domain 2 
of apical membrane antigen 1 (AMA1) as previously 
described [22] (see Additional file 1). TaqMan real-time 
PCR methods as previously described [23–26] were used 
to evaluate P. falciparum multidrug resistance gene 1 
(PfMDR1) copy number and single nucleotide polymor-
phisms (SNPs) at PfMDR1 codon positions 86, 184, 1034, 
and 1042.
Statistical analysis
Statistical analysis was performed using GraphPad 
Prism version 6.0 (GraphPad Software, Inc, San Diego, 
CA, USA). Comparison of IC50s attained from fresh and 
culture-adapted samples were made using Wilcoxon 
matched pair testing. Assay correlation was evaluated 
using Spearman’s correlation test. Wilcoxon match pair 
testing was also used to compare % parasitaemia at 72 h 
cultivation of drug assay for whole blood versus packed 
RBC specimens, and their IC50 results. Statistical signifi-
cance was defined as a P value <0.05.
Results
IEV drug susceptibility testing was performed on 20 
fresh P. falciparum isolates, attaining HRP-2 IC50 values 
for all samples. However, in trying to establish long-term 
culture of these 20 isolates, only 12 of 20 (60  %) could 
be recovered from cryopreservation and maintained 
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in vitro. There was no difference in parasitaemia among 
recovered (mean parasitaemia 2.4  %, range 0.8–10.6  %) 
and non-recovered (3.3  % mean parasitaemia, range 
1–13.8 %) isolates.
IC50s obtained from culture-adapted parasites were sig-
nificant lower than those from fresh isolates for all drugs 
tested in both the HRP-2 and SYBR Green I assays, with 
greater than a 50 % decline for the majority of drug-assay 
combinations (Fig. 1 and Additional file 2). The most dra-
matic decline was noted in MQ IC50 for nearly all isolates 
during in  vitro culture adaptation. While consistently 
higher IC50 was found in fresh isolates, the IC50s of fresh 
and culture-adapted isolates were significantly corre-
lated for all drugs except DHA when HRP-2 and SYBR 
Green I data were pooled (Fig.  2). There was a lack of 
correlation noted in some drugs when looking at HRP-2 
results alone, and all drugs for SYBR Green I alone (Addi-
tional file 2). This is likely due to the small sample sizes 
involved.
To examine the possible confounding effects of human 
WBCs in clinical specimens, the HRP-2 assay was run 
on whole blood and packed RBC specimens of 29 fresh 
P. falciparum isolates, side by side. Slightly reduced 
IC50s were found after removing WBC for most of the 
drugs tested, except for CQ (median difference = −0.7 
to −44.6, P < 0.05). This was not explained by effects of 
WBCs on parasite growth, as there were no differences 
in parasitaemia at 72 h in whole blood [geometric mean 
(range) of 0.9  % (0.1–4.6)] or packed RBC specimens 
[0.9 % (0.1–7.9)] (median difference of 0, P value 0.87).
To examine genetic constituents of original and cul-
tured adapted parasites, three polymorphic genes (msp1, 
msp2, and glurp), pfmdr1drug resistance markers and a 
hyper-variable region in ama1 domain II were compared 
between the paired original fresh and culture-adapted 
isolates. Msp1, msp2, and glurp genotyping indicated the 
same genetic pattern for original and culture adapted 
samples for all 12 cases. Polyclonal infections were 
detected in two of the 12 cases (OM144 and OM188) 
with all clones still present following the culture-adapta-
tion process (Additional file 3). Similarly, the same alleles 
of pfmdr1 SNPs were detected in both original and cul-
ture-adapted samples, and there were minimal changes 
in pfmdr1 copy number following culture adaptation 
(Additional file 4). Corresponding results were also found 
based on AMA1 sequence analysis (Additional file  1). 
Deep sequencing of the hyper-variable region of AMA1 
domain II detected four unique haplotypes among the 
12 cases. All cases appeared monoclonal in both original 
and culture-adapted samples, except for case OM144. 
Two AMA1 clones were detected in OM144 at origin, 
with a minority variant occurring at 1.3  % in the fresh 
isolate that was lost after culture adaptation.
Discussion
In vitro drug susceptibility results attained from fresh 
clinical isolates were compared and found to have 
reduced IC50 following cryopreservation and culture 
adaptation in an area of multidrug resistance in Cam-
bodia. These differences were true for both HRP-2 and 
SYBER Green I assays, and when the results from both 
assays were pooled, there was good correlation between 
results from fresh and culture-adapted isolates for most 
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Fig. 1 IC50 values were higher in 12 fresh Plasmodium falciparum isolates compared to when they were culture-adapted using both the HRP-2 
(black) and SYBR Green I (blue) assays. Median differences and P values from the Wilcoxon pair test for combined HRP-2 and SYBR Green I results are 
indicated in red
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change in genetic make-up between original and culture-
adapted isolates for the monoclonal infections, which 
predominated in this population. The overall IC50 reduc-
tion combined with the correlation between fresh isolates 
and culture-adapted drug susceptibility assays suggests 
the utility of both approaches, as long as there is consist-
ency of method, and remaining mindful of possible atten-
uation occurring with culture. However, clonal selection 
during culture adaptation in polyclonal samples may 
occur, suggesting a limitation on performance of culture-
based assays for parasite drug susceptibility of primary 
infections in high transmission areas where multiplicity 
of infection is expected to be high.
The reduced IC50 seen in culture-adapted samples 
compared to fresh isolates for the majority of commonly 
used drugs observed here has not been described in pre-
vious reports. A study of Kenyan isolates using the SYBR 
Green I assay showed no differences in IC50 between the 
original clinical isolates and culture for most drugs tested 
with the exception of MQ and AS which had higher IC50 
following culture adaptation than they did originally in 
the IEV assay [11]. However, potential sampling bias was 
noted due to different collection sites in hypo-endemic 
and holo-endemic areas used for the culture-adapted and 
IEV assays. In lower transmission settings as in the pre-
sent experiment, while there were clearly lower MQ IC50 
values in cryopreserved compared to fresh isolates for the 
HRP-2 assay, sample size for the comparable SYBR Green 
I assay comparison was limited to six isolates, revealing 
only a non-significant trend toward higher fresh isolate 
values (see Additional file  2). Another study using the 
schizont maturation assay showed increased IC50 follow-
ing culture adaptation, most notably for initially CQ-sen-
sitive isolates, which became CQ-resistant during culture 
adaptation [12]. Although parasite genetic data were not 
collected, this observation was hypothesized to be related 
to selection of CQ-resistant minority variant clones in 
culture attributed to parasite metabolic changes occur-
ring during culture adaptation [27, 28]. Given the pre-
dominance of polyclonal infections in Africa, and greater 
potential for differential parasite subpopulation selection 
during the culture adaptation process, the likelihood of 
extrapolating these findings to higher transmission set-
tings remains unclear.
Little evidence of parasite sub-population selection 
during culture adaptation was found in this study, based 
on limited molecular markers analysed. Indeed, poly-
clonal P. falciparum infections are relatively uncommon 
in lower transmission settings such as Cambodia [20]. 
The considerable attenuation of IC50 in culture observed 
here cannot be explained by loss or selection of minor-
ity variants. Given that P. falciparum W2 reference was 
tested as a quality control for inter-assay variation, the 
differences in IC50 are unlikely due to variation among 
lots of drug, reagents, and media used between the 
in  vitro and ex  vivo assays. One potential explanation 
would be that WBCs in clinical specimens may confound 
results by absorbing some quantity of drug, and increase 
IC50 measured in the IEV assay. This was supported by a 
slight reduction in IC50 after removing WBCs in a sepa-
rate experiment, but the effects were modest. Nonethe-
less, inhibitory effect of WBCs on parasite growth was 
not observed, and there were no differences in parasi-
taemia at 72 h of culture in fresh whole blood compared 
to packed RBC (WBC-depleted) culture. Given that this 
study looked at only a handful of the known molecular 
markers conferring anti-malarial resistance, there may 
be other as yet unidentified genetic and epigenetic fac-
tors, as well as changes in metabolic pathways that may 
explain the apparent alteration of drug susceptibility 
phenotypes between the original and culture-adapted 
isolates.
There was a modest decline in artemisinin IC50 fol-
lowing culture adaptation, more so for DHA than AS, 
and modest correlation in values between IEV and cul-
ture-based assessments. At the time of conducting this 
study, the ring-stage survival assay (RSA) for measuring 
artemisinin resistance in isolates was not yet available. 
Artemisinin (ART) susceptibility phenotypes based on % 
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Fig. 2 Correlations between IC50 values attained from paired fresh 
and culture adapted samples for 12 Plasmodium falciparum isolates 
using the combined values for both the HRP-2 and SYBR Green I 
assays. IC50 for each drug are presented in different colours, with 
unfilled and filled symbols representing HRP-2 and SYBR Green I IC50, 
respectively. Spearman ρ and P values from combined HRP-2 and 
SYBR Green I results are shown for each drug, with an overall Spear-
man’s correlation coefficient of 0.9 (P < 0.001)
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survival rate of RSA have been shown to be stage-depend-
ent [29–31]. Very early ring stages (0–3 h after invasion) 
have proven to be an appropriate stage for ART suscep-
tibility testing using the RSA (RSA0−3 h), as changes in 
% survival rate allow discrimination between ART-sen-
sitive and resistant parasites [29]. Obtaining very early 
ring stages using the in vitro RSA method requires tight 
synchronization of the parasite culture, whereas ex vivo 
staging of clinical isolates (age of ring) is crucial for inter-
preting results from the ex  vivo RSA. Even with limita-
tion on parasite staging of ex vivo fresh isolates that may 
affect assay accuracy, the previous report [29] showed 
good correlation between in vivo parasite clearance half-
life and ex vivo survival rate, and suggested ex vivo RSA 
may be an informative screening method for surveil-
lance of artemisinin resistance. On the other hand, the 
standard IC50 assay requires only moderate synchronicity 
of >80 % ring forms, regardless of the age of the ring. This 
level of synchronicity can be achieved in ex  vivo speci-
mens in which only ring stages are commonly found in 
blood circulation with later stages tending to adhere to 
endothelium, and in  vitro assay by simple sorbitol syn-
chronization of parasite culture before testing. Therefore, 
it is unlikely that the level of synchronicity had a signifi-
cant influence on the IC50 results, and explains the differ-
ences in IC50 between the in vitro and ex vivo assays.
Evidence of parasite sub-population selection in poly-
clonal infections during culture adaptation has been 
described in previous studies. Differences in pfmdr 1 gen-
otype pre- and post-culture have been described in poly-
clonal infections [24]. Loss of parasite sub-populations 
during culture adaptation were observed in 60–70  % of 
polyclonal samples collected from both Uganda and the 
China-Myanmar border [5, 6]. Fitness costs to resistant 
parasite sub-populations during in  vitro culture have 
been postulated to alter parasite genotype [5–7]. These 
alterations may confound in  vitro drug susceptibility 
results for culture-adapted parasites, obscuring poten-
tial correlations with the ex  vivo assay, particularly in 
high transmission areas where multiplicity of infection is 
high [2, 20, 32, 33]. On the contrary, little effect may be 
expected in low transmission areas where multiplicity of 
infection is low, as evidenced here in Cambodian isolates 
[20].
Conclusions
Study results suggest attenuation of in vitro drug resist-
ance phenotype following culture adaptation compared 
to fresh clinical isolates from Cambodia. This sup-
ports the use of the IEV assay as a tool for drug resist-
ance surveillance, saving considerable time and effort 
required to establish parasite cultures. In addition, the 
IEV approach may reduce limitations in recovery rates 
for cryopreserved specimens, and avoid the confounding 
effects of clonal selection for polyclonal infections during 
culture adaptation. Given limitations in field laboratory 
capabilities in many settings, in vitro drug susceptibility 
assay on culture-adapted parasite remains an informa-
tive tool, with the above-noted cautions, particularly in 
high transmission settings where multiplicity of infec-
tion is high. Potential variation between IEV and culture-
adapted results should be considered carefully when 
performing inter-laboratory comparisons where different 
methods have been used.
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